Male Osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 3, 2012, Pages 629-641

  Drake, Matthew T ^a   Khosla, Sundeep ^a  

^a MAYO CLINIC   (United States)

Author keywords

DXA; Epidemiology; Fracture; Men; Osteoporosis; QCT; Sex steroids

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTRADIOL; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SEX HORMONE; VITAMIN D; ZOLEDRONIC ACID;

AGING; BONE DENSITY; BONE MASS; BONE STRUCTURE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CORTICAL BONE; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; HIP FRACTURE; HORMONE ACTION; HUMAN; MALE; MEN'S HEALTH; OSTEOLYSIS; OSTEOPOROSIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOCIAL SUPPORT; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

AGING; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RANK LIGAND; RISK FACTORS;

EID: 84864799616     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.05.001     Document Type: Review

References (71)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94(6):646-650.
2. Melton L.J., Khosla S., Achenbach S.J., et al. Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men. Osteoporos Int 2000, 11(11):977-983.
3. Cooper C., Campion G., Melton L.J. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992, 2(6):285-289.
4. Johnell O., Kanis J.A. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004, 15(11):897-902.
5. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17(12):1726-1733.
6. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353(9156):878-882.
7. van Staa T.P., Dennison E.M., Leufkens H.G., et al. Epidemiology of fractures in England and Wales. Bone 2001, 29(6):517-522.
8. Schuit S.C., van der Klift M., Weel A.E., et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004, 34(1):195-202.
9. Jonsson B.Y., Siggeirsdottir K., Mogensen B., et al. Fracture rate in a population-based sample of men in Reykjavik. Acta Orthop Scand 2004, 75(2):195-200.
10. Cooper C., Cole Z.A., Holroyd C.R., et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 2011, 22(5):1277-1288.
11. Gullberg B., Johnell O., Kanis J.A. World-wide projections for hip fracture. Osteoporos Int 1997, 7(5):407-413.
12. Khosla S., Amin S., Orwoll E. Osteoporosis in men. Endocr Rev 2008, 29(4):441-464.
13. Diamond T.H., Thornley S.W., Sekel R., et al. Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 1997, 167(8):412-415.
14. Kiebzak G.M., Beinart G.A., Perser K., et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002, 162(19):2217-2222.
15. Bass E., French D.D., Bradham D.D., et al. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 2007, 17(7):514-519.
16. Poor G., Atkinson E.J., O'Fallon W.M., et al. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 1995, (319):260-265.
17. Schurch M.A., Rizzoli R., Mermillod B., et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996, 11(12):1935-1942.
18. Curtis J.R., McClure L.A., Delzell E., et al. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009, 24(8):956-962.
19. Shibli-Rahhal A., Vaughan-Sarrazin M.S., Richardson K., et al. Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos Int 2011, 22(12):2973-2980.
20. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002, 17(4):716-724.
21. O'Neill T.W., Felsenberg D., Varlow J., et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996, 11(7):1010-1018.
22. Davies K.M., Stegman M.R., Heaney R.P., et al. Prevalence and severity of vertebral fracture: the Saunders County Bone Quality Study. Osteoporos Int 1996, 6(2):160-165.
23. Santavirta S., Konttinen Y.T., Heliovaara M., et al. Determinants of osteoporotic thoracic vertebral fracture. Screening of 57,000 Finnish women and men. Acta Orthop Scand 1992, 63(2):198-202.
24. Szulc P., Munoz F., Marchand F., et al. Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS study. Osteoporos Int 2001, 12(4):302-310.
25. Melton L.J., Atkinson E.J., Cooper C., et al. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999, 10(3):214-221.
26. Hasserius R., Karlsson M.K., Nilsson B.E., et al. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 2003, 14(1):61-68.
27. Burger H., Van Daele P.L., Grashuis K., et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997, 12(1):152-157.
28. Center J.R., Bliuc D., Nguyen T.V., et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007, 297(4):387-394.
29. Looker A.C., Orwoll E.S., Johnston C.C., et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997, 12(11):1761-1768.
30. Melton L.J., Atkinson E.J., O'Connor M.K., et al. Bone density and fracture risk in men. J Bone Miner Res 1998, 13(12):1915-1923.
31. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010, 95(1):3-10.
32. Kanis J.A., Bianchi G., Bilezikian J.P., et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 2011, 22(11):2789-2798.
33. Silverman S.L., Madison R.E. Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California hospital discharge data. Am J Public Health 1988, 78(11):1482-1483.
34. Drake M.T., Murad M.H., Mauck K.F., et al. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012, 97(6):1861-1870.
35. Riggs B.L., Melton Iii L.J., Robb R.A., et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004, 19(12):1945-1954.
36. Turner C.H. Bone strength: current concepts. Ann N Y Acad Sci 2006, 1068:429-446.
37. Marshall L.M., Lang T.F., Lambert L.C., et al. Dimensions and volumetric BMD of the proximal femur and their relation to age among older U.S. men. J Bone Miner Res 2006, 21(8):1197-1206.
38. Khosla S., Riggs B.L., Atkinson E.J., et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 2006, 21(1):124-131.
39. Silva M.J., Gibson L.J. Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone 1997, 21(2):191-199.
40. Khosla S., Melton L.J., Atkinson E.J., et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83(7):2266-2274.
41. Slemenda C.W., Longcope C., Zhou L., et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997, 100(7):1755-1759.
42. Greendale G.A., Edelstein S., Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997, 12(11):1833-1843.
43. Center J.R., Nguyen T.V., Sambrook P.N., et al. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999, 84(10):3626-3635.
44. van den Beld A.W., de Jong F.H., Grobbee D.E., et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000, 85(9):3276-3282.
45. Amin S., Zhang Y., Sawin C.T., et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000, 133(12):951-963.
46. Szulc P., Munoz F., Claustrat B., et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001, 86(1):192-199.
47. Khosla S., Melton L.J., Atkinson E.J., et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001, 86(8):3555-3561.
48. Khosla S., Riggs B.L., Robb R.A., et al. Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J Clin Endocrinol Metab 2005, 90(9):5096-5103.
49. Gennari L., Merlotti D., Martini G., et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003, 88(11):5327-5333.
50. Mellstrom D., Vandenput L., Mallmin H., et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008, 23(10):1552-1560.
51. Khosla S., Melton L.J., Riggs B.L. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J Bone Miner Res 2011, 26(3):441-451.
52. Falahati-Nini A., Riggs B.L., Atkinson E.J., et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000, 106(12):1553-1560.
53. Nair K.S., Rizza R.A., O'Brien P., et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006, 355(16):1647-1659.
54. Wakley G.K., Schutte H.D., Hannon K.S., et al. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. J Bone Miner Res 1991, 6(4):325-330.
55. Sattin R.W., Lambert Huber D.A., DeVito C.A., et al. The incidence of fall injury events among the elderly in a defined population. Am J Epidemiol 1990, 131(6):1028-1037.
56. Paspati I., Galanos A., Lyritis G.P. Hip fracture epidemiology in Greece during 1977-1992. Calcif Tissue Int 1998, 62(6):542-547.
57. Stevens J.A., Sogolow E.D. Gender differences for non-fatal unintentional fall related injuries among older adults. Inj Prev 2005, 11(2):115-119.
58. Kennel K.A., Riggs B.L., Achenbach S.J., et al. Role of parathyroid hormone in mediating age-related changes in bone resorption in men. Osteoporos Int 2003, 14(8):631-636.
59. Boonen S., Mohan S., Dequeker J., et al. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 1999, 14(12):2150-2158.
60. Undale A.H., Westendorf J.J., Yaszemski M.J., et al. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc 2009, 84(10):893-902.
61. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343(9):604-610.
62. Ringe J.D., Faber H., Farahmand P., et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006, 26(5):427-431.
63. Orwoll E.S., Binkley N.C., Lewiecki E.M., et al. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010, 46(4):970-976.
64. Orwoll E.S., Miller P.D., Adachi J.D., et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010, 25(10):2239-2250.
65. Sambrook P.N., Roux C., Devogelaer J.P., et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012, 50(1):289-295.
66. Bauman W.A., Wecht J.M., Kirshblum S., et al. Effect of pamidronate administration on bone in patients with acute spinal cord injury. J Rehabil Res Dev 2005, 42(3):305-313.
67. Girotra M., Rubin M.R., Bilezikian J.P. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006, 7(1-2):113-121.
68. Murad M.H., Drake M.T., Mullan R.J., et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012, Mar 30, [Epub ahead of print].
69. Dawson-Hughes B., Harris S.S., Krall E.A., et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337(10):670-676.
70. Ross A.C., Manson J.E., Abrams S.A., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96(1):53-58.
71. Rosen C.J., Gallagher J.C. The 2011 IOM report on vitamin D and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 2011, 14(2):79-84.